Hopital Saint Eloi
- Address
- lock Available on a paid plan
Digestive System Diseases
Hopital Saint Eloi’s hepato‑gastro‑enterology department leads research on liver disease, biliary cancers and inflammatory bowel disorders, aiming to improve treatment outcomes and quality of life for patients.
- Hepatocellular carcinoma
- Advanced biliary tract cancers
- Ulcerative colitis
- Crohn's disease
- Non‑alcoholic steatohepatitis (NASH)
- Metabolic dysfunction‑associated steatohepatitis (MASH)
- Chronic hepatitis D infection
- Esophageal achalasia
The site currently supports 28 clinical trials with a team of 33 investigators, fostering collaborations across Europe.
Hemic and Lymphatic Diseases
Studies at the hospital target blood‑derived malignancies, exploring novel immunotherapies and targeted agents to enhance survival in patients with aggressive cancers.
- Acute myeloid leukemia
- Myelodysplastic syndrome
- Mantle cell lymphoma
- Non‑Hodgkin lymphoma
- Chronic lymphocytic leukemia
- Richter’s syndrome
- Relapsed/refractory marginal zone lymphoma
- B‑cell NHL
Researchers are evaluating safety and efficacy of bispecific antibodies and cellular therapies to address unmet needs in these diseases.
Immune System Diseases
The department investigates immune‑mediated gastrointestinal conditions, testing biologic agents that modulate inflammatory pathways to achieve remission and reduce disease burden.
- Moderately to severely active ulcerative colitis
- Moderately to severely active Crohn's disease
- Idiopathic hypersomnia
Ongoing trials compare new monoclonal antibodies with standard therapies, seeking faster symptom control and long‑term safety.
Neoplasms
A broad oncology program examines solid tumors such as melanoma and renal cell carcinoma, integrating checkpoint inhibitors and targeted drugs to prevent recurrence after surgery.
- Hepatocellular carcinoma
- Melanoma
- Renal cell carcinoma
- Lymphatic malformations associated with PIK3CA mutation
- Advanced biliary tract cancers
The aim is to identify regimens that improve overall survival while maintaining quality of life for cancer survivors.
Cardiovascular Diseases
Clinical work includes evaluating oral anticoagulants to lower the risk of major adverse cardiac events in patients who have experienced a heart attack, focusing on safety and reduction of recurrent events.
- Acute coronary syndrome
The trial design measures cardiovascular death, myocardial infarction and ischemic stroke as composite outcomes.
Virus Diseases
Research on chronic viral hepatitis aims to assess long‑term liver outcomes with novel antivirals, addressing a key public‑health challenge in the region.
- Chronic hepatitis D infection
Participants are monitored for liver‑related events to determine the therapeutic benefit of emerging treatments.
Nutritional and Metabolic Diseases
The site conducts trials on metabolic liver disorders, testing agents that may resolve steatohepatitis and reverse fibrosis, thereby preventing progression to cirrhosis.
- Non‑alcoholic steatohepatitis (NASH)
- Metabolic dysfunction‑associated steatohepatitis (MASH)
- Fibrosis
Endpoints include histological improvement and reduction of liver‑related mortality.
Environment and Public Health
A focus on public health evaluates procedural interventions and post‑procedure medication strategies to reduce complications and improve patient safety in everyday clinical practice.
- Acid reflux management after POEM for esophageal achalasia
- Health outcomes following endoscopic myotomy
Findings aim to guide best practices for clinicians and inform health‑policy decisions in the wider community.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 11 therapeutic areas and 15 of 83 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 77 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 17 by active trials.
- 1Abivax2active
lock +16 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC5trials
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hopital Saint Eloi
lock Showing 1 of 44 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Double-Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis | Gilead Sciences Inc. | Phase II | Recruiting | Apr 2024 | — |
IMP list
lock Showing 1 of 83 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 6 | Unknown | 2018-07-09 | 2026-01-06 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.